A detailed history of Cibc Private Wealth Group, LLC transactions in Dynavax Technologies Corp stock. As of the latest transaction made, Cibc Private Wealth Group, LLC holds 6,500 shares of DVAX stock, worth $80,340. This represents 0.0% of its overall portfolio holdings.

Number of Shares
6,500
Previous 6,500 -0.0%
Holding current value
$80,340
Previous $72,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$10.73 - $12.58 $28,434 - $33,337
-2,650 Reduced 28.96%
6,500 $72,000
Q1 2024

May 10, 2024

BUY
$11.7 - $14.98 $107,055 - $137,067
9,150 New
9,150 $113,000
Q4 2022

Jun 01, 2023

BUY
$10.27 - $13.29 $110,597 - $143,120
10,769 New
10,769 $114,000
Q3 2022

Nov 14, 2022

SELL
$9.93 - $17.44 $5,104 - $8,964
-514 Reduced 4.56%
10,769 $112,000
Q2 2022

Aug 03, 2022

SELL
$7.45 - $12.83 $16,963 - $29,213
-2,277 Reduced 16.79%
11,283 $142,000
Q3 2021

Nov 12, 2021

BUY
$9.16 - $19.83 $124,209 - $268,894
13,560 New
13,560 $260,000
Q4 2019

Jan 30, 2020

SELL
$3.46 - $6.93 $74,390 - $148,995
-21,500 Closed
0 $0
Q3 2019

Oct 16, 2019

SELL
$2.69 - $4.85 $2,690 - $4,850
-1,000 Reduced 4.44%
21,500 $77,000
Q1 2019

May 10, 2019

BUY
$7.08 - $12.09 $35,400 - $60,450
5,000 Added 28.57%
22,500 $164,000
Q4 2018

Feb 05, 2019

BUY
$8.14 - $13.28 $52,910 - $86,320
6,500 Added 59.09%
17,500 $160,000
Q3 2018

Nov 14, 2018

BUY
$11.85 - $16.0 $47,400 - $64,000
4,000 Added 57.14%
11,000 $136,000
Q2 2018

Aug 02, 2018

BUY
$15.15 - $20.75 $49,995 - $68,475
3,300 Added 89.19%
7,000 $107,000
Q1 2018

May 17, 2018

BUY
$14.65 - $19.9 $39,555 - $53,729
2,700 Added 270.0%
3,700 $73,000
Q4 2017

Feb 12, 2018

BUY
$17.3 - $24.08 $17,300 - $24,080
1,000
1,000 $19,000

Others Institutions Holding DVAX

About DYNAVAX TECHNOLOGIES CORP


  • Ticker DVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 126,474,000
  • Market Cap $1.56B
  • Description
  • Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. It also manufa...
More about DVAX
Track This Portfolio

Track Cibc Private Wealth Group, LLC Portfolio

Follow Cibc Private Wealth Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cibc Private Wealth Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cibc Private Wealth Group, LLC with notifications on news.